Join our daily newsletter At The Bell to receive exclusive market insights
- Imugene (IMU) begins dosing patients in the third cohort of its phase one trial of a cancer treatment
- Three patients have begun the dosing schedule of the optimal biological dose of 100 micrograms of the treatment, PDI-Vaxx
- The drug has been designed to treat tumours and phase one of the trial is assessing the drug’s safety and tolerability
- IMU expects the dosing level to be ratified at the next Cohort Review Committee (CRC) hearing which is scheduled for the first week of October
- Shares are trading 5.15 per cent higher at 35.8 cents at 10:50 am AEST
Imugene (IMU) has begun dosing patients in the third cohort of its phase one trial of a cancer treatment.
The treatment, PD1-Vaxx, has been designed to treat tumours such as lung cancer by producing an anti-cancer effect.
The phase one trial has been assessing the drug’s safety and tolerability, with the first cohort trialing a dosage of 10 micrograms, the second with 50 micrograms and now the third cohort will assess the optimal biological dose of 100 micrograms.
IMU announced in April that cohort three would be going ahead, following data from cohort two which was reviewed by the Cohort Review Committee (CRC) who determined the drug candidate safe with no dose-limiting toxicities.
Three patients have reportedly begun their dosing schedule and IMU expects the dosing level to be ratified at the next CRC hearing which is scheduled for the first week of October.
The company explained that the clinical results so far had continued to indicate that PD1-Vaxx was showing early signs of an immune response in patients, with antibodies to the target biomarker PD-1 evident in validated assays.
MD and CEO Leslie Chong said completion of the mono-therapy component of the phase one trial would be a milestone for the company and for clinicians treating Australians with lung cancer.
Shares were trading 5.15 per cent higher at 35.8 cents at 10:50 am AEST.
